Amgen Inc. (NASDAQ:AMGN) Shares Sold by First PREMIER Bank

First PREMIER Bank cut its position in Amgen Inc. (NASDAQ:AMGN) by 0.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,559 shares of the medical research company’s stock after selling 55 shares during the period. First PREMIER Bank’s holdings in Amgen were worth $2,987,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. DB Fitzpatrick & Co Inc increased its holdings in shares of Amgen by 145.4% in the second quarter. DB Fitzpatrick & Co Inc now owns 4,311 shares of the medical research company’s stock valued at $1,347,000 after purchasing an additional 2,554 shares during the period. CGC Financial Services LLC grew its holdings in Amgen by 250.0% during the second quarter. CGC Financial Services LLC now owns 175 shares of the medical research company’s stock worth $55,000 after acquiring an additional 125 shares during the period. Baader Bank Aktiengesellschaft grew its holdings in Amgen by 97.1% during the second quarter. Baader Bank Aktiengesellschaft now owns 1,577 shares of the medical research company’s stock worth $492,000 after acquiring an additional 777 shares during the period. 180 Wealth Advisors LLC grew its holdings in Amgen by 354.7% during the second quarter. 180 Wealth Advisors LLC now owns 8,990 shares of the medical research company’s stock worth $2,923,000 after acquiring an additional 7,013 shares during the period. Finally, Lockerman Financial Group Inc. grew its holdings in Amgen by 8.7% during the second quarter. Lockerman Financial Group Inc. now owns 1,208 shares of the medical research company’s stock worth $377,000 after acquiring an additional 97 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AMGN has been the topic of several analyst reports. William Blair raised Amgen from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. StockNews.com raised Amgen from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 target price (up from $375.00) on shares of Amgen in a report on Wednesday, August 7th. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $320.00 to $335.00 in a report on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Eleven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus price target of $326.89.

Amgen Trading Up 0.8 %

Amgen stock traded up $2.66 during trading on Thursday, reaching $325.39. 1,886,797 shares of the company were exchanged, compared to its average volume of 2,623,715. Amgen Inc. has a 52-week low of $248.38 and a 52-week high of $346.85. The company has a market capitalization of $174.55 billion, a P/E ratio of 46.48, a PEG ratio of 2.78 and a beta of 0.58. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98. The stock’s 50 day simple moving average is $319.66 and its two-hundred day simple moving average is $299.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 156.21% and a net margin of 12.74%. The company had revenue of $8.39 billion for the quarter, compared to analysts’ expectations of $8.35 billion. During the same quarter in the previous year, the business posted $5.00 EPS. The business’s quarterly revenue was up 20.1% compared to the same quarter last year. On average, equities research analysts expect that Amgen Inc. will post 19.5 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were given a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.77%. Amgen’s payout ratio is 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.